Mehmet MURAT, Fatih Mehmet TÜRKÇÜ, Alparslan ŞAHİN, Çetin Akpolat

Evaluation of choroidal changes in patients with ocular toxoplasmosis using spectral domain optical coherence tomography

We aimed to examine the choroidal changes in ocular toxoplasmosis with spectral domain optical coherence tomography using the enhanced depth-imaging mode. The clinical and laboratory data and spectral domain optical coherence tomography images of patients diagnosed with ocular toxoplasmosis and admitted to Dicle University, Department of Ophthalmology were analyzed retrospectively. The demographic properties such as best-corrected visual acuity intraocular pressure, biomicroscopic findings and dilated fundus examination were noted. The patients were categorized into three groups: active ocular toxoplasmosis, inactive ocular toxoplasmosis and healthy control groups. Enhanced depth-imaging coherence tomography images of both lesion area and subfoveal region were obtained in patients with active and inactive ocular toxoplasmosis, whereas only the enhanced depth-imaging coherence tomography images of subfoveal region were obtained in control group to measure choroidal thickness. A total of 54 subjects were evaluated including 20 individuals in the control group, 10 patients in active ocular toxoplasmosis group and 24 patients in inactive ocular toxoplasmosis group. No statistical significance was observed among the groups in terms of age, gender and intraocular pressure. Significant differences were noted in BCVA and SFCT among three groups. The mean ChT of the lesion area was significantly thicker in active ocular toxoplasmosis group than inactive ocular toxoplasmosis group (p=0.001). Monitoring of choroid is possible by EDI technique of spectral domain optical coherence tomography. This method is easily applicable and beneficial in the examining of ocular toxoplasmosis. Best-corrected visual acuity and the choroidal thickness in lesion area may vary according to activity.

PDF

___

Zimmerman LE. Ocular pathology of toxoplasmosis. Sys Ophthalmol 1961;6:832-76.

Lima GS, Saraiva PG, Saraiva FP. Current therapy of acquired ocular toxoplasmosis: a review. J Ocul Pharmacol Ther. 2015;31:511-7.

Yehoshua Z, Rosenfeld PJ, Albini TA. Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures. Semin Ophthalmol. 2011;26:167-80.

Manjunath V, Taha M, Fujimoto JG, Choroidal thickness in normal eyes measured using Cirrus HD optical coherence tomography. Am J Ophthalmol. 2010;150:325-9.

Potsaid B, Gorczynska I, Srinivasan VJ, et al. Ultrahigh speed spectral/ Fourier domain OCT ophthalmic imaging at 70,000 to 312,500 axial scans per second. Opt Express. 2008;16:15149-69.

Spaide RF, Koizumi H, Pozonni MC. Enhanced depth imaging spectraldomain optical coherence tomography. Am J Ophthalmol 2008;146:496-500.

Ikuno Y, Kawaguchi K, Nouchi T, et al. Choroidal thickness in healthy Japanese subjects. Invest Ophthalmol Vis Sci. 2010;51:2173-6.

Imamura Y, Fujiwara T, Margolis R, et al. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009;29:1469-73.

Lütjen-Drecoll E. Choroidal innervation in primate eyes. Exp Eye Res. 2006;82:357-61.

Kiel JW, van Heuven WA. Ocular perfusion pressure and choroidal blood flow in the rabbit. Invest Ophthalmol Vis Sci. 1995;36:579-85.

Kiel JW. Endothelin modulation of choroidal blood flow in the rabbit. Exp Eye Res. 2000;71:543-50.

Evliyaoğlu F, Akpolat Ç, Mustafa Kurt M, et al. Retinal vascular caliber changes after topical nepafenac treatment for diabetic macular edema. Curr Eye Res. 2018 ;43:357-61.

Kurt MM, Çekiç O, Akpolat Ç, Effects of intravitreal ranibizumab and bevacizumab on the retinal vessel size in diabetic macular edema. Retina. 2018;36:1120-6.

Saffra NA, Seidman CJ, Weiss LM. Ocular toxoplasmosis: controversies in primary and secondary prevention. J Neuroinfect Dis. 2013;4. pii:235689.

Ramrattan RS, van der Schaft TL, Mooy CM, et al. Morphometric analysis of Bruch’s membrane, the choriocapillaris and the choroid in aging. Invest Ophthalmol Vis Sci. 1994;35:2857-64.

Quaranta M, Arnold J, Coscas G, et al. Indocyanine green angiographic features of pathologic myopia. Am J Ophthalmol. 1996;122:663-71.

Boonarpha N, Zheng Y, Stangos AN, et al. Standardization of choroidal thickness measurements using enhanced depth imaging optical coherence tomography. Int J Ophthalmol. 2015;8:484-91.

Ko A, Cao S, Pakzad-Vaezi K, et al. Optical coherence tomography-based correlation between choroidal thickness and drusen load in dry age-related macular degeneration. Retina. 2013;33:1005-10.

Ishikawa S, Taguchi M, Muraoka T, et al. Changes in subfoveal choroidal thickness associated with uveitis activity in patients with Behçet’s disease. Br J Ophthalmol. 2014;98:1508-13.

Goldenberg D, Goldstein M, Loewenstein A, et al. Vitreal, retinal and choroidal findings in active and scarred toxoplasmosis lesions: a prospective study by spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2013;251:2037-45.

Oréfice JL, Costa RA, Scott IU, et al. Spectral optical coherence tomography findings in patients with ocular toxoplasmosis and active satellite lesions (MINAS Report 1). Acta Ophthalmol. 2013;91:e41-7.

. Ding X, Li J, Zeng J, et al. Choroidal thickness in healthy Chinese subjects. Invest Ophthalmol VisSci. 2011;52:9555-60.

Freitas-Neto CA, Cao JH, Oréfice JL, et al. Increased submacular choroidal Thickness in active, isolated, extramacular toxoplasmosis. Ophthalmology. 2016;123:222-4

. McCourt EA, Cadena BC, Barnett CJ, et al. Measurement of subfoveal choroidal thickness using spectral domain optical coherence tomography. Ophthalmic Surg Lasers Imaging. 2010;41:S28-33.

. Coskun E, Gurler B, Pehlivan Y, et al. Enhanced depth imaging optical coherence tomography findings in Behçet disease. Ocul Immunol Inflamm. 2013;21:440-5.